Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Total Liabilities (2020 - 2026)

GeneDx Holdings has reported Total Liabilities over the past 7 years, most recently at $252.2 million for Q1 2026.

  • Quarterly Total Liabilities rose 33.41% to $252.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $252.2 million through Mar 2026, up 33.41% year-over-year, with the annual reading at $215.5 million for FY2025, 23.77% up from the prior year.
  • Total Liabilities was $252.2 million for Q1 2026 at GeneDx Holdings, up from $215.5 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $296.0 million in Q2 2022 and troughed at $163.0 million in Q3 2023.
  • The 5-year median for Total Liabilities is $195.1 million (2024), against an average of $208.6 million.
  • The largest YoY upside for Total Liabilities was 42.92% in 2022 against a maximum downside of 53.72% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $237.2 million in 2022, then dropped by 19.6% to $190.7 million in 2023, then decreased by 8.71% to $174.1 million in 2024, then rose by 23.77% to $215.5 million in 2025, then rose by 17.0% to $252.2 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Total Liabilities are $252.2 million (Q1 2026), $215.5 million (Q4 2025), and $201.6 million (Q3 2025).